Literature DB >> 28440864

Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old.

Christine D Hsu1, Xiaoyan Wang1, David V Habif1, Cynthia X Ma2, Kimberly J Johnson1.   

Abstract

BACKGROUND: Few population-based studies have examined the association between health insurance status and breast cancer stage at diagnosis and survival. The degree to which sociodemographic characteristics explain this association is also unclear. This study examined associations between insurance status and sociodemographic characteristics and stage at diagnosis and survival.
METHODS: Using the Surveillance, Epidemiology, and End Results 18 registries database, we identified 52,048 women aged 18 to 64 years who were diagnosed with breast cancer in 2007 and 2008. Associations between insurance status and sociodemographic variables and stage at diagnosis and survival were examined with logistic and Cox proportional hazards regression models to calculate adjusted odds ratios (ORs), hazard ratios (HRs), and associated confidence intervals (CIs).
RESULTS: The odds of a later stage breast cancer diagnosis were increased in women with Medicaid (OR, 2.36; 95% CI, 2.19-2.55) and no insurance (OR, 2.64; 95% CI, 2.29-3.04) versus private insurance, in women who had reported black race (OR, 1.18; 95% CI, 1.09-1.28) versus white race, in women who were unmarried (OR, 1.25; 95% CI, 1.18-1.33) versus married at diagnosis, and in women who were 18 to 39 years old (OR, 1.29; 95% CI, 1.18-1.41) versus 40 to 64 years old at diagnosis. The hazard of breast cancer death was increased in association with Medicaid (HR, 1.40; 95% CI, 1.30-1.51) and no insurance (HR, 1.61; 95% CI, 1.41-1.84) versus private insurance, with reported black race (HR, 1.39; 95% CI, 1.29-1.50) versus reported white race, and with being unmarried (HR, 1.19; 95% CI, 1.12-1.27) versus being married.
CONCLUSIONS: Insurance status at diagnosis and sociodemographic factors are associated with breast cancer mortality. Factors underlying these associations warrant further study. Cancer 2017;123:3125-31.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  Affordable Care Act; Epidemiology; Medicaid; Surveillance; and End Results (SEER); breast cancer; health insurance

Mesh:

Year:  2017        PMID: 28440864     DOI: 10.1002/cncr.30722

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  Leveraging an Implementation Science Framework to Adapt and Scale a Patient Navigator Intervention to Improve Mammography Screening Outreach in a New Community.

Authors:  Melissa A Simon; Catherine A O'Brian; Jacqueline M Kanoon; Alnierys Venegas; Stacy Ignoffo; Charlotte Picard; Kristi L Allgood; Laura Tom; Helen Margellos-Anast
Journal:  J Cancer Educ       Date:  2020-06       Impact factor: 2.037

2.  Naïve Bayesian network-based contribution analysis of tumor biology and healthcare factors to racial disparity in breast cancer stage-at-diagnosis.

Authors:  Yi Luo; Henry Carretta; Inkoo Lee; Gabrielle LeBlanc; Debajyoti Sinha; George Rust
Journal:  Health Inf Sci Syst       Date:  2021-09-24

3.  Sister, Give Me Your Hand: a Qualitative Focus Group Study on Beliefs and Barriers to Mammography Screening in Black Women During the COVID-19 Era.

Authors:  Vivian J Bea; Bonnie Jerome-D'Emilia; Francesse Antoine; Plyshette Wiggins; Diane Hyman; Evelyn Robles-Rodriguez
Journal:  J Racial Ethn Health Disparities       Date:  2022-06-22

4.  Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.

Authors:  Yunan Han; Zhi-Feng Miao; Min Lian; Lindsay L Peterson; Graham A Colditz; Ying Liu
Journal:  Breast Cancer Res Treat       Date:  2020-09-14       Impact factor: 4.872

5.  Integrating access to care and tumor patterns by race and age in the Carolina Breast Cancer Study, 2008-2013.

Authors:  Marc A Emerson; Yvonne M Golightly; Xianming Tan; Allison E Aiello; Katherine E Reeder-Hayes; Andrew F Olshan; H Shelton Earp; Melissa A Troester
Journal:  Cancer Causes Control       Date:  2020-01-16       Impact factor: 2.506

6.  Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study.

Authors:  Rin Ogiya; Naoki Niikura; Hiraku Kumamaru; Yoshinori Takeuchi; Takuho Okamura; Takayuki Kinoshita; Kenjiro Aogi; Keisei Anan; Kotaro Iijima; Takanori Ishida; Takayuki Iwamoto; Masaaki Kawai; Yasuyuki Kojima; Takashi Sakatani; Yasuaki Sagara; Naoki Hayashi; Hideji Masuoka; Masayuki Yoshida; Hiroaki Miyata; Hitoshi Tsuda; Shigeru Imoto; Hiromitsu Jinno
Journal:  Breast Cancer Res Treat       Date:  2020-08-20       Impact factor: 4.872

7.  Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis.

Authors:  Joshua P Kronenfeld; Emily L Ryon; David Goldberg; Rachel M Lee; Adam Yopp; Annie Wang; Ann Y Lee; Sommer Luu; Cary Hsu; Eric Silberfein; Maria C Russell; Nipun B Merchant; Neha Goel
Journal:  HPB (Oxford)       Date:  2020-12-29       Impact factor: 3.842

8.  Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients.

Authors:  Jeffrey E Johnson; Paula D Strassle; Guilherme C de Oliveira; Chris B Agala; Philip Spanheimer; Kristalyn Gallagher; David Ollila; Hyman Muss; Stephanie Downs-Canner
Journal:  Breast Cancer Res Treat       Date:  2021-06-26       Impact factor: 4.624

9.  Relationship between insurance status and outcomes for patients with breast cancer in Missouri.

Authors:  Jennifer L Berrian; Ying Liu; Min Lian; Chester L Schmaltz; Graham A Colditz
Journal:  Cancer       Date:  2020-11-17       Impact factor: 6.921

10.  Survival among patients with glioma in the US Military Health System: A comparison with patients in the Surveillance, Epidemiology, and End Results program.

Authors:  Jie Lin; Julie A Bytnar; Brett J Theeler; Katherine A McGlynn; Craig D Shriver; Kangmin Zhu
Journal:  Cancer       Date:  2020-04-14       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.